Ongoing Clinical Trials

Advancing the Clinical Evidence for Miro3D

Reprise Biomedical is committed to advancing the science of wound care through continued clinical research and the development of high-quality evidence supporting the use of Miro3D® Wound Matrix. As part of this commitment, Reprise Biomedical is sponsoring a prospective, randomized controlled clinical trial evaluating Miro3D Wound Matrix in the treatment of chronic, non-healing diabetic foot ulcers (DFUs).

The study is designed to evaluate the clinical effectiveness of Miro3D Wound Matrix used in conjunction with standard of care compared with standard of care alone in patients with Wagner Grade 1 and 2 DFUs.

For the most current information regarding study status, eligibility criteria, study locations, investigators, and other details, please visit the official study record on ClinicalTrials.gov.

Clinical Trial Information

Study Title: Miro3D Wound Matrix for Treatment of Diabetic Foot Ulcers
Sponsor: Reprise Biomedical, Inc.
ClinicalTrials.gov Identifier: NCT07632001

SM-00458 Rev. A 10/26